Market Overview

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Flex Pharma, Inc. To Contact The Firm

Share:

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds
investors in Flex Pharma, Inc. ("Flex" or the "Company") (NASDAQ:FLKS)
of the August 18, 2018 deadline to seek the role of lead plaintiff in a
federal securities class action that has been filed against the Company.

If you invested in Flex Pharma, Inc. stock or options between
November 6, 2017 and June 12, 2018
and would like to discuss your
legal rights, click here: www.faruqilaw.com/FLKS.
There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at
877-247-4292
or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

The lawsuit has been filed in the U.S. District Court for the Southern
District of New York on behalf of all those who purchased Flex
securities between November 6, 2017 and June 12, 2018 (the "Class
Period"). The case, Rumaldo v. Flex Pharma, Inc., No. 18-cv-05493
was filed on June 19, 2018, and has been assigned to Judge Vernon Speede
Broderick.

The lawsuit focuses on whether the Company and its executives violated
federal securities laws by overstating the viability and approval
prospects for its product candidate FLX-787 for the treatment of ALS and
CMT.

Specifically, on June 13, 2018, the Company announced that it had plans
to halt two ongoing Phase 2 clinical trials for FLX-787, the Company's
treatment for amyotrophic lateral sclerosis, citing oral tolerability
concerns observed in both studies. Flex further announced that the
Company would restructure its organization to reduce costs, including
reducing its workforce by approximately 60%, and that Flex's Board was
exploring "strategic alternatives, including the potential sale or
merger of the company."

On this news, Flex's share price fell from $4.18 at close on June 12,
2018 to $1.04 on June 13, 2018—a $3.14 or 75.12% drop, causing harm to
investors.

The court-appointed lead plaintiff is the investor with the largest
financial interest in the relief sought by the class who is adequate and
typical of class members who directs and oversees the litigation on
behalf of the putative class. Any member of the putative class may move
the Court to serve as lead plaintiff through counsel of their choice, or
may choose to do nothing and remain an absent class member. Your ability
to share in any recovery is not affected by the decision to serve as a
lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding
Flex Pharma's conduct to contact the firm, including whistleblowers,
former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is
Faruqi & Faruqi, LLP (www.faruqilaw.com).
Prior results do not guarantee or predict a similar outcome with respect
to any future matter. We welcome the opportunity to discuss your
particular case. All communications will be treated in a confidential
manner.

View Comments and Join the Discussion!